Reengineering Ponatinib to Minimize Cardiovascular Toxicity

Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed as an inhibitor of the BCR-ABL oncogene and is among the mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Hnatiuk, Anna P., Bruyneel, Arne A.N., Tailor, Dhanir, Pandrala, Mallesh, Dheeraj, Arpit, Li, Wenqi, Serrano, Ricardo, Feyen, Dries A.M., Vu, Michelle M., Amatya, Prashila, Gupta, Saloni, Nakauchi, Yusuke, Morgado, Isabel, Wiebking, Volker, Liao, Ronglih, Porteus, Matthew H., Majeti, Ravindra, Malhotra, Sanjay V., Mercola, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620869/
https://www.ncbi.nlm.nih.gov/pubmed/35763671
http://dx.doi.org/10.1158/0008-5472.CAN-21-3652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620869/
https://www.ncbi.nlm.nih.gov/pubmed/35763671
http://dx.doi.org/10.1158/0008-5472.CAN-21-3652

Ejemplares similares